MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10096-025-05059-y

Медицинская библиотека · European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025

Which antimicrobial treatment for patients with bloodstream infection during ECMO support?

Massart Nicolas, Ortuno Sofia, Vidal Charles, Henri Samuel, Rozé Hadrien, Bouglé Adrien, Manicone Francesca, Bidar Frank, Assouline Benjamin, Masi Paul, Hraiech Sami, Nesseler Nicolas, de Montmollin Etienne, Luyt Charles-Edouard

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

OJECTIVE: We aim to describe a large, multicenter cohort of patients with bloodstream infection (BSI) acquired during extracorporeal membrane oxygenation (ECMO) support.

METHODS

We conducted a retrospective observational study in 12 Europeans ICUs. Only patients who developed a BSI of unknown source during ECMO support were included in the present analysis. Primary aim was to describe BSI epidemiology in patients with ECMO support. Secondary objectives were to describe antimicrobial susceptibility of incriminated micro-organisms.

RESULTS

One hundred and eighty-two patients were included. Main reason for ECMO support was ARDS, followed by cardiogenic shock and post-cardiotomy. Half of the patients (51.9%) received early antimicrobial therapy. Main incriminated microorganisms were Enterococcus sp. (37.4%), Enterobacterales (26.9%), coagulase negative Staphylococci (15.9%) and Gram negative bacilli (11.5%). Multi drug resistant organisms (MDRO) were incriminated in 26 (14.3%) BSI and were mainly extended spectrum producing-Enterobacterales (17/26). Antimicrobial therapy was considered as appropriate in 130 patients (71.4%). Patients who received inappropriate antimicrobial therapy were more frequently infected with MDRO. Only 59 (32.4%) of cases were susceptible to 3rd generation cephalosporin while association of piperacillin/tazobactam with vancomycin was considered appropriate in 155 cases (85.2%) as compared with 168 cases (92.3%) for carbapenems combined with vancomycin.

CONCLUSION

Enterococcus sp. was incriminated in about a third of BSI among patients with ECMO support. High appropriateness would only be obtained with piperacilline/tazobactam or carbapenems in association with vancomycin while 3rd generation cephalosporin would have failed in the majority of BSI cases.

CLINICAL TRIAL NUMBER: Not applicable.

Для цитирования: Massart Nicolas, Ortuno Sofia, Vidal Charles, Henri Samuel, Rozé Hadrien, Bouglé Adrien, Manicone Francesca, Bidar Frank, Assouline Benjamin, Masi Paul, Hraiech Sami, Nesseler Nicolas, de Montmollin Etienne, Luyt Charles-Edouard. Which antimicrobial treatment for patients with bloodstream infection during ECMO support?. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2025. DOI: 10.1007/s10096-025-05059-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.